Zimmer Holdings is a global leader in the development and manufacture of orthopaedic implants and related products, focusing on enhancing the quality of life for individuals suffering from conditions related to bones and joints. The company specializes in a wide range of surgical products and services, including joint replacement systems, trauma products, and a variety of surgical instruments. Zimmer Holdings also invests in innovative technologies and solutions to improve surgical outcomes and patient satisfaction, catering to healthcare professionals and institutions worldwide. With a commitment to advancing orthopaedic care, the company plays a crucial role in both the medical community and patient rehabilitation processes. Read More
Medical device company Zimmer Biomet (NYSE:ZBH) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $2...
Medical device company Zimmer Biomet (NYSE:ZBH) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 9.3% year on year to $2.09 b...
Medical device company Zimmer Biomet (NYSE:ZBH) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know. Zimm...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing
CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA), cementing its plans to finalize the Biologics License Application (BLA) for ReNu, its
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
As of March 16, 2026, the medical technology landscape is grappling with a stark reminder of the vulnerabilities inherent in the digital shift of healthcare. Stryker Corporation (NYSE: SYK), a global titan in medical devices and equipment, finds itself at the center of a developing storm following a massive cyberattack that has sent ripples through [...]
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...
Over the past six months, Zimmer Biomet’s stock price fell to $99.27. Shareholders have lost 6.1% of their capital, which is disappointing considering the S&P 500 has climbed by 7.6%. This might have investors contemplating their next move.
